VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter. ...

Cardiac dosing limit removed and path forward to dose selection identifiedLONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosin ...

Core Insights - The FDA has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for treating adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer [1][2][3] Group 1: Clinical Data and Trials - The Breakthrough Therapy designation is supported by clinical data from the Phase 1/2 ReDiscover trial, which evaluated zovegalisib's safety, tolerability, pharmacokinetics, and preliminary antitumor activity [3][4] - Initial Phase 1/2 data for zovegalisib + fulvestrant at the 400mg BID fed dose will be presented at the ESMO Targeted Anticancer Therapies Congress on March 16, 2026 [1][4] - The ReDiscover trial included data from two doses: 600mg BID fasted (N=52) and 400mg BID fed (N=57), with the latter being the dose used in the ongoing Phase 3 trial [3] Group 2: Market Potential and Patient Impact - Approximately 40% of patients with HR+/HER2- advanced breast cancer have PIK3CA mutations, leading to limited treatment options after CDK4/6 inhibitors [2][8] - Zovegalisib has the potential to address a significant portion of the estimated 140,000 patients with HR+, HER2- breast cancer with a PI3Kα mutation annually in the U.S. [5] Group 3: Mechanism and Innovation - Zovegalisib is the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome limitations of traditional PI3Kα inhibitors [6] - The development of zovegalisib utilized advanced computational methods to elucidate conformational differences between wild-type and mutant PI3Kα [6]

Core Insights - Axsome Therapeutics Inc. (NASDAQ:AXSM) is recognized as a promising mid-cap stock by leading investors, with H.C. Wainwright raising its price target from $200 to $260 while maintaining a Buy rating [1] - The company reported interim unaudited financial results for Q4 2025, projecting total product revenue of approximately $196 million [1] Revenue Projections - Axsome anticipates overall product revenue of around $638.5 million for fiscal year 2025, representing a 66% increase compared to fiscal year 2024, surpassing H.C. Wainwright's estimate of $628.3 million [2] - The primary product, AUVELITY, is expected to generate net sales of about $155.1 million in Q4 and $507.1 million for the full year 2025, significantly exceeding the firm's annual sales estimate of $397 million [2] Performance of Other Products - Other products, such as SUNOSI, are also projected to perform well, with expected revenues of $36.7 million in Q4 and $124.8 million for the entire year [3] - Axsome Therapeutics focuses on developing novel therapies for central nervous system (CNS) disorders in the US [3]

Group 1 - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is recognized as a mid-cap stock to buy, with Truist Securities raising its price target to $230 from $220 while maintaining a Buy rating [1] - The increase in price target is attributed to positive results from the HERIZON-GEA trial, leading to higher estimations for Ziihera [1][3] - Jazz Pharmaceuticals plans to file a supplemental Biologics License Application (sBLA) in the first half of 2026 to obtain a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy [2] Group 2 - Truist Securities expects strong commercial adoption of Jazz Pharmaceuticals' products following clearance based on clinical data, with over 90% prescriber crossover between GEA and biliary tract cancer (BTC) [3] - The company develops treatments for serious illnesses, with key products including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos [3]

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Ana ...

Core Viewpoint - Pyxis Oncology, Inc. is undergoing a leadership transition with the appointment of Thomas Civik as Interim CEO, following the departure of Lara S. Sullivan, to ensure continuity in advancing the company's strategic and clinical goals [1][2][3]. Leadership Transition - Thomas Civik, a long-time member of the Board of Directors and an experienced biotechnology executive, has been appointed as Interim Chief Executive Officer [2][4]. - Lara S. Sullivan has stepped down from her roles as President, CEO, and Chief Medical Officer after six years of leadership [2][4]. - The Board of Directors is conducting a structured search for a permanent CEO while maintaining operational continuity through the established clinical development leadership team [3][4]. Company Focus and Clinical Programs - Pyxis Oncology's lead program, micvotabart pelidotin (MICVO), is currently in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a Phase 1/2 study in combination with Merck's pembrolizumab [4][8]. - The company aims to prioritize the execution of its clinical programs and upcoming milestones, focusing on improving patient outcomes in difficult-to-treat cancers [5][8]. Background of Interim CEO - Thomas Civik previously served as President and CEO of Five Prime Therapeutics, leading its acquisition by Amgen for $1.9 billion in April 2021 [5][6]. - He has extensive experience in oncology development, having held leadership roles at Genentech for 17 years, overseeing key therapies such as Avastin and Tecentriq [6]. About Pyxis Oncology - Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers, with MICVO being a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin [7][10]. - MICVO is designed to treat solid tumors through a multi-pronged mechanism of action, including direct tumor cell killing and mobilizing an anti-tumor immune response [10].

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation a ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher target. Pixabay/Public Domain Leerink decreased its fourth-quarter 2025 earnings per share forecast by 29%, from $1.65 to $1.19, citing exp ...

Core Viewpoint - AstraZeneca PLC (NASDAQ:AZN) is enhancing its weight management portfolio through a strategic collaboration with CSPC Pharmaceuticals to develop next-generation therapies for obesity and type 2 diabetes across eight programs [1][2]. Group 1: Collaboration Details - The agreement includes the initial progress of four programs, utilizing CSPC's AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing technology [2]. - AstraZeneca will gain exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, which features one clinical-ready asset, SYH2082, and three preclinical programs [2]. Group 2: Existing Portfolio - The collaboration complements AstraZeneca's existing weight management portfolio, which includes a range of next-generation treatments targeting obesity and related complications [3]. - Current treatments in the pipeline include elecoglipron (AZD5004), AZD9550, and AZD6234, along with several preclinical assets [3]. Group 3: Company Overview - AstraZeneca PLC is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines [4]. - The company distributes its products through local representative offices and distributors [4].